Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation followed by dose expansion study of TL32711 in combination with
5-Azacitidine in subjects with Myelodysplastic syndrome who are naïve, have relapsed or have
failed prior 5-azacitidine therapy. Pre-clinical and mechanistic studies support that
5-Azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.